Status:
COMPLETED
Effect of Metformin on Gut Microbiota Changes and Glycemic Control of Newly Diagnosed Type 2 Diabetes
Lead Sponsor:
Shenzhen People's Hospital
Conditions:
Type 2 Diabetes
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
This study was aimed to investigate the effect of metformin on the gut microbiota and glycemic control in newly diagnosed type 2 diabetes patients.
Detailed Description
This study was aimed to investigate the effect of metformin on the gut microbiota and glycemic control in newly diagnosed type 2 diabetes patients. All the recurited patients were treated with metform...
Eligibility Criteria
Inclusion
- newly diagnosis type 2 diabetes ,HbA1c \>7 %
Exclusion
- history of cardiovascular disease, hypertension, severe renal dysfunction defined as glomerular filtration rate \< 45 mL/min/1.73 m2; severe illness or diabetic ketoacidosis within 30 days, inability to tolerate ≥500 mg metformin twice per day and pregnancy.
Key Trial Info
Start Date :
March 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 30 2018
Estimated Enrollment :
52 Patients enrolled
Trial Details
Trial ID
NCT04426422
Start Date
March 1 2017
End Date
September 30 2018
Last Update
June 11 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shenzhen People' S Hospital
Shenzhen, Guangdong, China, 518000